REPORT OF THE COMMITTEE
Tuesday, April 23, 2013
The Standing Senate Committee on Social Affairs, Science and Technology
has the honour to present its
TWENTY-SECOND REPORT
Your committee, which was authorized by the Senate on Tuesday, November 22, 2011 to examine and report on prescription pharmaceuticals in Canada, respectfully requests funds for the fiscal year ending March 31, 2014.
Pursuant to Chapter 3:06, section 2(1)(c) of the Senate Administrative Rules, the budget submitted to the Standing Committee on Internal Economy, Budgets and Administration and the report thereon of that committee are appended to this report.
Respectfully submitted,
Original signed by:
KELVIN K. OGILVIE
Chair
STANDING COMMITTEE ON
SOCIAL AFFAIRS, SCIENCE AND TECHNOLOGY
SPECIAL STUDY ON PRESCRIPTION PHARMACEUTICALS IN CANADA
APPLICATION FOR BUDGET AUTHORIZATION
FOR THE FISCAL YEAR ENDING MARCH 31, 2014
Extract from the Journals of the Senate, Tuesday, November 22, 2011:
The Honourable Senator Ogilvie, pursuant to notice of November 17, 2011, moved:
That the Senate Standing Committee on Social Affairs, Science and Technology be authorized to examine and report on prescription pharmaceuticals in Canada, including but not limited to:
(a) the process to approve prescription pharmaceuticals with a particular focus on clinical trials;
(b) the post-approval monitoring of prescription pharmaceuticals;
(c) the off-label use of prescription pharmaceuticals; and
(d) the nature of unintended consequences in the use of prescription pharmaceuticals.
That the committee submit its final report no later than December 31, 2013, and that the committee retain until March 31, 2014, all powers necessary to publicize its findings.
The question being put on the motion, it was adopted.
Gary W. O’Brien
Clerk of the Senate
APPENDIX (B) TO THE REPORT
T he Standing Committee on Internal Economy, Budgets and Administration has examined the budget presented to it by the Standing Senate Committee on Social Affairs, Science and Technology for the proposed expenditures of the said Committee for the fiscal year ending March 31, 2014 for the purpose of its special study on prescription pharmaceuticals in Canada, as authorized by the Senate on Tuesday, November 22, 2011. The approved budget is as follows:
General Expenses | $ 30,600 |
TOTAL | $ 30,600 |
Respectfully submitted,
DAVID TKACHUK
Chair